1-(4-((4-((3,4-dichlorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop -2-en-1-one | 1092364-46-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(4-((4-((3,4-dichlorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop -2-en-1-one
• 英文别名: US11365189, Ex. No. 25；1-[4-[4-(3,4-dichloroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one
• CAS: 1092364-46-9
• 化学式: C₂₃H₂₂Cl₂N₄O₃
• 分子量: 473.359
• InChiKey: ZTQLMGBKQNFQRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  76.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] HETEROCYCLIC INHIBITORS OF TYROSINE KINASE<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE TYROSINE KINASE
  申请人：UNIV TEXAS

  公开号：WO2020219904A1

  公开（公告）日：2020-10-29

  The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.

  本公开涉及杂环化合物和方法，这些方法可能作为HER2或EGFR的抑制剂，用于治疗或预防疾病，包括癌症。
• NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS
  申请人：Lee Kwang-Ok

  公开号：US20100179120A1

  公开（公告）日：2010-07-15

  The present invention provides a novel amide derivative and a pharmaceutically acceptable salt thereof which selectively and effectively inhibits the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase, and a pharmaceutical composition comprising same as an active ingredient.

  本发明提供了一种新型酰胺衍生物及其药学上可接受的盐，该酰胺衍生物能够选择性和有效地抑制由表皮生长因子受体过度表达引起的癌细胞生长，并且还能够防止由EGFR酪氨酸激酶突变引起的药物耐受性的发展。本发明还提供了一种包含该酰胺衍生物作为活性成分的药物组合物。
• QUINAZOLINE DERIVATIVE AND USE THEREOF
  申请人：Medshine Discovery Inc.

  公开号：EP3733663A1

  公开（公告）日：2020-11-04

  The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.

  本发明涉及一系列喹唑啉化合物，特别是由式（I）表示的化合物、其异构体或其药学上可接受的盐、其药物组合物，以及其作为泛 HER 酪氨酸激酶抑制剂的用途。
• Heterocyclic inhibitors of tyrosine kinase
  申请人：Board of Regents, The University of Texas System

  公开号：US11365189B2

  公开（公告）日：2022-06-21

  The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.

  本公开涉及可用作 HER2 或表皮生长因子受体抑制剂用于治疗或预防疾病（包括癌症）的杂环化合物和方法。
• HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
  申请人：Board of Regents, The University of Texas System

  公开号：US20200354343A1

  公开（公告）日：2020-11-12

  The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.